ATL-962: AZM will begin a 3-month double-blind, placebo-controlled European Phase IIb trial of 3 doses of ATL-962 to treat obesity in 340 clinically obese patie

Alizyme plc (LSE:AZM), Cambridge, U.K.
Product: ATL-962

Read the full 73 word article

How to gain access

Continue reading with a
two-week free trial.